Becton Dickinson Down 23% in 2025 at $205, Trades 13–14x Forward P/E
Becton Dickinson shares fell 23% in 2025, trading near $205 in early January 2026 after challenges from its Biosciences and Diagnostics spinoff and cautious guidance. Forward P/E of 13–14x sits below historical averages, implying 28–40% undervaluation, while completed spinoff proceeds, margin expansion and FCF yield above 5% support recovery.
1. 2025 Performance and Spinoff Headwinds
Becton Dickinson experienced a 23% share price drop in 2025, driven by challenges in separating its Biosciences and Diagnostics unit, policy headwinds and conservative guidance. Trading around $205 in early January 2026, the company faced a temporary pullback during the business separation process.
2. Valuation Metrics and Undervaluation
The stock trades at a forward P/E of 13–14x, below its historical average, suggesting an intrinsic valuation gap of 28–40%. This lower multiple reflects market skepticism but highlights a potential bargain for value-focused investors.
3. Recovery Catalysts
Key catalysts include proceeds from the completed diagnostics and biosciences spinoff, planned share buybacks, and anticipated margin expansion driven by growing drug delivery demand. Recent momentum showed positive stock returns over the past six months, signaling early investor confidence.
4. Balance Sheet and Cash Flow Strength
Financial strength indicators remain solid, with free cash flow yield exceeding 5% and interest coverage above five times operating income. Long-term debt levels are stable, and liquidity metrics point to a sound balance sheet capable of funding ongoing R&D investments.